Activation of AMP-activated protein kinase a1 mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis

Human Molecular Genetics

Volumn 24, Issue 3, 2015, Pages 787-801

  Liu, Yu Ju ^a,b   Ju, Tz Chuen ^b   Chen, Hui Mei ^b   Jang, Yu Sung ^b   Lee, Li Ming ^c   Lai, Hsing Lin ^b   Tai, Hua Chia ^d   Fang, Jim Min ^d   Lin, Yun Lian ^e   Tu, Pang Hsien ^b   Chern, Yijuang ^a,b,e  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR; CYCLIC AMP; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA 1; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG; AMPK ALPHA1 SUBUNIT, MOUSE; DNA BINDING PROTEIN; PRKAA1 PROTEIN, HUMAN; TDP-43 PROTEIN, HUMAN; TDP-43 PROTEIN, MOUSE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE LOCATION; GENE REPRESSION; HUMAN; MALE; MIDDLE AGED; MOTONEURON; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SPINAL CORD; TRANSGENIC MOUSE; ANIMAL; CELL LINE; CELL NUCLEUS; DISEASE MODEL; GENE EXPRESSION REGULATION; METABOLISM; MOUSE;

MUS MUSCULUS;

ADULT; AGED; AMP-ACTIVATED PROTEIN KINASES; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CELL LINE; CELL NUCLEUS; CYTOPLASM; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; MOTOR NEURONS; SPINAL CORD;

EID: 84922429320     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu497     Document Type: Article

References (58)

1. Bento-Abreu, A., Van Damme, P., Van Den Bosch, L. and Robberecht, W. (2010) The neurobiology of amyotrophic lateral sclerosis. Eur. J. Neurosci., 31, 2247-2265.
2. Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T., Bruce, J., Schuck, T., Grossman, M., Clark, C.M. et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314, 130-133.
3. Talbot, K. (2011) Familial versus sporadic amyotrophic lateral sclerosis-a false dichotomy? Brain, 134, 3429-3431.
4. Byrne, S., Walsh, C., Lynch, C., Bede, P., Elamin, M., Kenna, K., McLaughlin, R. and Hardiman, O. (2011) Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry, 82, 623-627.
5. Talbot, K. (2009) Another gene for ALS: mutations in sporadic cases and the rare variant hypothesis. Neurology, 73, 1172-1173.
6. Al-Chalabi, A. and Hardiman, O. (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat. Rev. Neurol., 9, 617-628.
7. Siciliano, G., Carlesi, C., Pasquali, L., Piazza, S., Pietracupa, S., Fornai, F., Ruggieri, S. and Murri, L. (2010) Clinical trials for neuroprotection in ALS. CNS Neurol. Disord. Drug Targets, 9, 305-313.
8. Wang, I.F., Wu, L.S., Chang, H.Y. and Shen, C.K. (2008) TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J. Neurochem., 105, 797-806.
9. Buratti, E., De Conti, L., Stuani, C., Romano, M., Baralle, M. and Baralle, F. (2010) Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J., 277, 2268-2281.
10. Buratti, E., De Conti, L., Stuani, C., Romano, M., Baralle, M. and Baralle, F. (2010) Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J., 277, 2268-2281.
11. Giordana, M.T., Piccinini, M., Grifoni, S., De Marco, G., Vercellino, M., Magistrello, M., Pellerino, A., Buccinna, B., Lupino, E. and Rinaudo, M.T. (2009) TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol., 20, 351-360.
12. Lagier-Tourenne, C., Polymenidou, M.and Cleveland, D.W. (2010) TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet., 19, R46-R64.
13. Urushitani, M., Sato, T., Bamba, H., Hisa, Y. and Tooyama, I. (2010) Synergistic effect between proteasome and autophagosome in the clearance of polyubiquitinated TDP-43. J. Neurosci. Res., 88, 784-797.
14. D'Amico, E., Factor-Litvak, P., Santella, R.M. and Mitsumoto, H. (2013) Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic. Biol. Med., 65, 509-527.
15. Cohen, T.J., Hwang, A.W., Unger, T., Trojanowski, J.Q. and Lee, V.M. (2012) Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. EMBO J., 31, 1241-1252.
16. Capitanio, D., Vasso, M., Ratti, A., Grignaschi, G., Volta, M., Moriggi, M., Daleno, C., Bendotti, C., Silani, V. and Gelfi, C. (2012) Molecular signatures of amyotrophic lateral sclerosis disease progression in hind and forelimb muscles of an SOD1(G93A) mouse model. Antioxid. Redox Signal., 17, 1333-1350.
17. Wang, P. and Jin, T. (2010) Hydrogen peroxide stimulates nuclear import of the POU homeodomain protein Oct-1 and its repressive effect on the expression of Cdx-2. BMC Cell Biol., 11, 56.
18. Wang, W., Fan, J., Yang, X., Furer-Galban, S., Lopez de Silanes, I., von Kobbe, C., Guo, J., Georas, S.N., Foufelle, F., Hardie, D.G. et al. (2002) AMP-activated kinase regulates cytoplasmic HuR. Mol. Cell Biol., 22, 3425-3436.
19. Kodiha, M., Crampton, N., Shrivastava, S., Umar, R. and Stochaj, U. (2010) Traffic control at the nuclear pore. Nucleus, 1, 237-244.
20. Kosako, H., Yamaguchi, N., Aranami, C., Ushiyama, M., Kose, S., Imamoto, N., Taniguchi, H., Nishida, E. and Hattori, S. (2009) Phosphoproteomics reveals new ERK MAP kinase targets and links ERK to nucleoporin-mediated nuclear transport. Nat. Struct. Mol. Biol., 16, 1026-1035.
21. Ayala, V., Granado-Serrano, A.B., Cacabelos, D., Naudi, A., Ilieva, E.V., Boada, J., Caraballo-Miralles, V., Llado, J., Ferrer, I., Pamplona, R. et al. (2011) Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: implications in ALS. Acta Neuropathol., 122, 259-270.
22. Long, Y.C. and Zierath, J.R. (2006) AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Invest., 116, 1776-1783.
23. Hardie, D.G., Ross, F.A. and Hawley, S.A. (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol., 13, 251-262.
24. Ju, T.C., Lin, Y.S. and Chern, Y. (2012) Energy dysfunction in Huntington's disease: insights from PGC-1alpha, AMPK, andCKB.Cell Mol. Life Sci., 69, 4107-4120.
25. Lim, M.A., Selak, M.A., Xiang, Z., Krainc, D., Neve, R.L., Kraemer, B.C., Watts, J.L. and Kalb, R.G. (2012) Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease. J. Neurosci., 32, 1123-1141.
26. Vingtdeux, V., Davies, P., Dickson, D.W. and Marambaud, P. (2011) AMPK is abnormally activated in tangle-and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol., 121, 337-349.
27. Ju, T.C., Chen, H.M., Lin, J.T., Chang, C.P., Chang, W.C., Kang, J.J., Sun, C.P., Tao, M.H., Tu, P.H., Chang, C. et al. (2011) Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J. Cell Biol., 194, 209-227.
28. Hawley, S.A., Davison, M., Woods, A., Davies, S.P., Beri, R.K., Carling, D. and Hardie, D.G. (1996) Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J. Biol. Chem., 271, 27879-27887.
29. Corton, J.M., Gillespie, J.G., Hawley, S.A. and Hardie, D.G. (1995) 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem., 229, 558-565.
30. Wang, W., Li, L., Lin, W.L., Dickson, D.W., Petrucelli, L., Zhang, T. and Wang, X. (2013) The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum. Mol. Genet., 22, 4706-4719.
31. Chen, L., Xu, B., Liu, L., Luo, Y., Yin, J., Zhou, H., Chen, W., Shen, T., Han, X. and Huang, S. (2010) Hydrogen peroxide inhibits mTOR signaling by activation ofAMPKalpha leading to apoptosis of neuronal cells. Lab. Invest., 90, 762-773.
32. Shan, X., Vocadlo, D. and Krieger, C. (2009) Mislocalization of TDP-43 in the G93A mutant SOD1 transgenic mouse model of ALS. Neurosci. Lett., 458, 70-74.
33. Cassada, D.C., Tribble, C.G., Kaza, A.K., Fiser, S.M., Long, S.M., Linden, J., Rieger, J.M., Kron, I.L. and Kern, J.A. (2001) Adenosine analogue reduces spinal cord reperfusion injury in a time-dependent fashion. Surgery, 130, 230-235.
34. Kaelin-Lang, A., Lauterburg, T. and Burgunder, J.M. (1999) Expression of adenosine A2a receptors gene in the olfactory bulb and spinal cord of rat and mouse. Neurosci. Lett., 261, 189-191.
35. Chen, J.B., Liu, E.M., Chern, T.R., Yang, C.W., Lin, C.I., Huang, N.K., Lin, Y.L., Chern, Y., Lin, J.H. and Fang, J.M. (2011) Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection. Chem. Med. Chem., 6, 1390-1400.
36. Huang, N.K., Lin, J.H., Lin, J.T., Lin, C.I., Liu, E.M., Lin, C.J., Chen, W.P., Shen, Y.C., Chen, H.M., Chen, J.B. et al. (2011) A new drug design targeting the adenosinergic system for Huntington's disease. PLoS ONE, 6, e20934.
37. Stallings, N.R., Puttaparthi, K., Luther, C.M., Burns, D.K. and Elliott, J.L. (2010) Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis., 40, 404-414.
38. Davis, J., Maillet, M., Miano, J.M. and Molkentin, J.D. (2012) Lost in transgenesis: a user's guide for genetically manipulating the mouse in cardiac research. Circ. Res., 111, 761-777.
39. Kodiha, M., Tran, D., Morogan, A., Qian, C. and Stochaj, U. (2009) Dissecting the signaling events that impact classical nuclear import and target nuclear transport factors. PLoS ONE, 4, e8420.
40. Robertson, J., Sanelli, T., Xiao, S., Yang, W., Horne, P., Hammond, R., Pioro, E.P. and Strong, M.J. (2007) Lack of TDP-43 abnormalities in mutant SOD1transgenic mice shows disparity with ALS. Neurosci. Lett., 420, 128-132.
41. Boillee, S. and Cleveland, D.W. (2008) Revisiting oxidativedamage inALS: microglia, Nox, and mutant SOD1. J. Clin. Invest., 118, 474-478.
42. Pokrishevsky, E., Grad, L.I., Yousefi, M., Wang, J., Mackenzie, I.R. and Cashman, N.R. (2012) Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS ONE, 7, e35050.
43. Henderson, J.T., Javaheri, M., Kopko, S. and Roder, J.C. (1996) Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine. J. Neurosci., 16, 7574-7582.
44. Andreassen, O.A., Dedeoglu, A., Klivenyi, P., Beal, M.F. and Bush, A.I. (2000) N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport, 11, 2491-2493.
45. Wu, L.S., Cheng, W.C. and Shen, C.K. (2013) Similar dose-dependence of motor neuron cell death caused by wild type human TDP-43 and mutants with ALS-associated amino acid substitutions. J. Biomed. Sci., 20, 33.
46. Nishimura, A.L., Zupunski, V., Troakes, C., Kathe, C., Fratta, P., Howell, M., Gallo, J.M., Hortobagyi, T., Shaw, C.E. and Rogelj, B. (2010) Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain, 133, 1763-1771.
47. Wang, W., Yang, X., Kawai, T., Lopez de Silanes, I., Mazan-Mamczarz, K., Chen, P., Chook, Y.M., Quensel, C., Kohler, M. and Gorospe, M. (2004) AMP-activated protein kinase-regulated phosphorylation and acetylation of importin alpha1: involvement in the nuclear import of RNA-binding protein HuR. J. Biol. Chem., 279, 48376-48388.
48. Dagon, Y., Avraham, Y. and Berry, E.M. (2006) AMPK activation regulates apoptosis, adipogenesis, and lipolysis by eIF2alpha in adipocytes. Biochem. Biophys. Res. Commun., 340, 43-47.
49. Kim, H.J., Raphael, A.R., Ladow, E.S., McGurk, L., Weber, R.A., Trojanowski, J.Q., Lee, V.M., Finkbeiner, S., Gitler, A.D. and Bonini, N.M. (2014) Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat. Genet., 46, 152-160.
50. Perera, N.D., Sheean, R.K., Scott, J.W., Kemp, B.E., Horne, M.K. and Turner, B.J. (2014) Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models. PLoS ONE, 9, e90449.
51. Vaisman, N., Lusaus, M., Nefussy, B., Niv, E., Comaneshter, D., Hallack, R. and Drory, V.E. (2009) Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? J. Neurol. Sci., 279, 26-29.
52. Association, A.D. (2009) Standards of medical care in diabetes-2009. Diabetes Care, 32, S13-S61.
53. Kaneb, H.M., Sharp, P.S., Rahmani-Kondori, N. and Wells, D.J. (2011) Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS ONE, 6, e24189.
54. Potenza, R.L., Armida, M., Ferrante, A., Pezzola, A., Matteucci, A., Puopolo, M. and Popoli, P. (2013) Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. Res., 91, 585-592.
55. Cashman, N.R., Durham, H.D., Blusztajn, J.K., Oda, K., Tabira, T., Shaw, I.T., Dahrouge, S. and Antel, J.P. (1992) Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev. Dyn., 194, 209-221.
56. Hylden, J.L. and Wilcox, G.L. (1980) Intrathecal morphine in mice: a new technique. Eur. J. Pharm., 67, 313-316.
57. Li, H.Y., Yeh, P.A., Chiu, H.C., Tang, C.Y. and Tu, B.P. (2011) Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation. PloS ONE, 6, e23075.
58. Chien, C.L., Wu, Y.S., Lai, H.L., Chen, Y.H., Jiang, S.T., Shih, C.M., Lin, S.S., Chang, C. and Chern, Y. (2010) Impaired water reabsorption inmice deficient in the type VI adenylyl cyclase (AC6). FEBS Lett., 584, 2883-2890.